Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 290

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden

Open access
Stone, Meredith L., Chiappinelli, Katherine B., Li, Huili, Murphy, Lauren M., Travers, Meghan E., Topper, Michael J., Mathios, Dimitrios, Lim, Michael, Shih, Ie-Ming, Wang, Tian-Li, Hung, Chien-Fu, Bhargava, Vipul, Wiehagen, Karla R., Cowley, Glenn S., Bachman, Kurtis E., Strick, Reiner, Strissel, Pamela L., Baylin, Stephen B., Zahnow, Cynthia A.·2017·Proceedings of the National Academy of Sciences

Abstract

Significance: Therapies that activate the host immune system have shown tremendous promise for a variety of solid tumors. However, in most cancer types, fewer than half of patients respond to these immunotherapies. We propose epigenetic therapy as a mechanism to sensitize tumors to immune checkpoint therapy. We have shown that inhibiting DNA methylation triggers a viral defense pathway in tumors. Here we show that epigenetic therapy in a mouse model of ovarian cancer increases the numbers of activated immune cells, and that this is dependent on the interferon antiviral response. The combination of epigenetic therapy and immune checkpoint blockade leads to the greatest reduction in tumor burden and increase in survival, and may hold the greatest promise for patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1712514114

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 290

Metadata

Authors
Stone, M. L., Chiappinelli, K. B., Li, H., Murphy, L. M., Travers, M. E., Topper, M. J., Mathios, D., Lim, M., Shih, I.-M., Wang, T.-L., Hung, C.-F., Bhargava, V., Wiehagen, K. R., Cowley, G. S., Bachman, K. E., Strick, R., Strissel, P. L., Baylin, S. B., & Zahnow, C. A.
Venue
Proceedings of the National Academy of Sciences
Published
2017-12-04
Volume
114
Issue
51
Pages
E10981-E10990
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2772046262
Cited by
290
References
20
FWCI
9.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. https://app.cochat.ai/papers/10.1073/pnas.1712514114
The paper
Stone, M. L., Chiappinelli, K. B., Li, H., Murphy, L. M., Travers, M. E., Topper, M. J., Mathios, D., Lim, M., Shih, I.-M., Wang, T.-L., Hung, C.-F., Bhargava, V., Wiehagen, K. R., Cowley, G. S., Bachman, K. E., Strick, R., Strissel, P. L., Baylin, S. B., & Zahnow, C. A. (2017). Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1712514114

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.